Market Update (NYSE:ACT): Actavis Confirms Generic Neupro® Patent Challenge

[PR Newswire] – DUBLIN, Aug. 22, 2014 /PRNewswire/ — Actavis plc (ACT) today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking . . . → Read More: Market Update (NYSE:ACT): Actavis Confirms Generic Neupro® Patent Challenge Similar Articles: Company Update (NYSE:ACT): Actavis Announces Positive Topline Results From The Phase III Program Of Ceftazidime-Avibactam In Patients With Complicated Intra-Abdominal Infections(cIAI) Company Update: Pfizer Inc (NYSE:PFE) – Teva settles patent suit with Pfizer over Celebrex Company Update: Johnson & Johnson (NYSE:JNJ) – EU regulators fine J&J, Novartis for generic drug deal
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.